Resapp Health Ltd
ASX:RAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (8.8), the stock would be worth AU$0.13 (37% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.1 | AU$0.21 |
0%
|
| 3-Year Average | 8.8 | AU$0.13 |
-37%
|
| 5-Year Average | 8.8 | AU$0.13 |
-37%
|
| Industry Average | 2.4 | AU$0.03 |
-83%
|
| Country Average | 1.7 | AU$0.02 |
-88%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Resapp Health Ltd
ASX:RAP
|
33.5m AUD | 14.1 | -3.1 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 22.3 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 5.2 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.5B USD | 7.9 | 28.1 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14B AUD | 45 | 60.7 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 2.2 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.2B SEK | 17.7 | 91.5 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.1B USD | 1 | 35.7 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 9.1 | 18.9 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
283.9B INR | 8.8 | 42.8 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.1B CNY | 2.9 | -62.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Resapp Health Ltd
Glance View
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.
